The decision to include these medical devices in the list of reimbursed medical devices was made at the meeting of the Council on Reimbursed Medical Devices and will take effect in June, immediately after publication in the Official Monitor.
According to official estimates, about 600 patients will benefit from this opportunity annually, for which the state will allocate a budget of about 25 million lei. The cost of annual provision of one patient will exceed 43 thousand lei.
Patients will be able to choose one of the three models of sensors authorized by the Agency for Medicines and Medical Devices in pharmacies operating under a contract with the National Health Insurance Company. At the same time, the authorities stress that the list remains open: other manufacturers can also submit dossiers for authorization and subsequent inclusion of their products in the reimbursement program.
Family physicians and endocrinologists will be authorized to prescribe sensors for continuous glucose monitoring. The introduction of continuous monitoring technology is an important step in the modern management of type 1 diabetes, offering an effective alternative to the classic method of testing with frequent finger pricks. The use of these technologies helps to prevent severe episodes of hypo- and hyperglycemia, reduces the risk of long-term complications and significantly improves the quality of life of patients. Thanks to this measure, the state facilitates access to advanced medical solutions, providing the necessary support to both young patients and their families.
According to the data of the Ministry of Health for the end of 2025, about 142 thousand people in Moldova, including more than 700 minors, suffer from diabetes. About 10 thousand cases of the disease are detected annually, and this trend is growing.
